JP6666852B2 - 前立腺がん再発の予後に関する遺伝子発現パネル - Google Patents

前立腺がん再発の予後に関する遺伝子発現パネル Download PDF

Info

Publication number
JP6666852B2
JP6666852B2 JP2016565119A JP2016565119A JP6666852B2 JP 6666852 B2 JP6666852 B2 JP 6666852B2 JP 2016565119 A JP2016565119 A JP 2016565119A JP 2016565119 A JP2016565119 A JP 2016565119A JP 6666852 B2 JP6666852 B2 JP 6666852B2
Authority
JP
Japan
Prior art keywords
prostate cancer
collection
individual
signature genes
signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016565119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503527A (ja
JP2017503527A5 (enExample
Inventor
マリアナ カーラ スターン
マリアナ カーラ スターン
ヤツェク ピンスキー
ヤツェク ピンスキー
ジアン−ビン ファン
ジアン−ビン ファン
Original Assignee
イルミナ インコーポレイテッド
イルミナ インコーポレイテッド
ユニヴァーシティ オブ サウザーン カリフォルニア
ユニヴァーシティ オブ サウザーン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イルミナ インコーポレイテッド, イルミナ インコーポレイテッド, ユニヴァーシティ オブ サウザーン カリフォルニア, ユニヴァーシティ オブ サウザーン カリフォルニア filed Critical イルミナ インコーポレイテッド
Publication of JP2017503527A publication Critical patent/JP2017503527A/ja
Publication of JP2017503527A5 publication Critical patent/JP2017503527A5/ja
Application granted granted Critical
Publication of JP6666852B2 publication Critical patent/JP6666852B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2016565119A 2014-01-16 2015-01-16 前立腺がん再発の予後に関する遺伝子発現パネル Expired - Fee Related JP6666852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461928361P 2014-01-16 2014-01-16
US61/928,361 2014-01-16
PCT/US2015/011824 WO2015109234A1 (en) 2014-01-16 2015-01-16 Gene expression panel for prognosis of prostate cancer recurrence

Publications (3)

Publication Number Publication Date
JP2017503527A JP2017503527A (ja) 2017-02-02
JP2017503527A5 JP2017503527A5 (enExample) 2018-03-01
JP6666852B2 true JP6666852B2 (ja) 2020-03-18

Family

ID=52435027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565119A Expired - Fee Related JP6666852B2 (ja) 2014-01-16 2015-01-16 前立腺がん再発の予後に関する遺伝子発現パネル

Country Status (7)

Country Link
US (3) US10364469B2 (enExample)
EP (1) EP3094747B1 (enExample)
JP (1) JP6666852B2 (enExample)
CN (2) CN112322735A (enExample)
AU (3) AU2015206336B2 (enExample)
CA (1) CA2935720A1 (enExample)
WO (1) WO2015109234A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935720A1 (en) 2014-01-16 2015-07-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
EP4546353A3 (en) * 2017-07-21 2025-07-23 The Board of Trustees of the Leland Stanford Junior University Systems and methods for analyzing mixed cell populations
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
CN107699564B (zh) * 2017-10-23 2019-09-20 中国科学院苏州生物医学工程技术研究所 人前列腺癌早期诊断用长链非编码rna序列及其应用
US10769783B2 (en) * 2018-02-09 2020-09-08 Case Western Reserve University Predicting prostate cancer biochemical recurrence using combined nuclear NF-KB/P65 localization and gland morphology
WO2019195268A2 (en) 2018-04-02 2019-10-10 Grail, Inc. Methylation markers and targeted methylation probe panels
US11348239B2 (en) 2018-05-14 2022-05-31 Tempus Labs, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
US11741365B2 (en) 2018-05-14 2023-08-29 Tempus Labs, Inc. Generalizable and interpretable deep learning framework for predicting MSI from histopathology slide images
US10957041B2 (en) 2018-05-14 2021-03-23 Tempus Labs, Inc. Determining biomarkers from histopathology slide images
US11348240B2 (en) * 2018-05-14 2022-05-31 Tempus Labs, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
US11348661B2 (en) 2018-05-14 2022-05-31 Tempus Labs, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
AU2019351130B2 (en) 2018-09-27 2025-10-23 GRAIL, Inc Methylation markers and targeted methylation probe panel
WO2020092808A1 (en) 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
GB2612911B (en) * 2019-02-14 2023-11-22 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
WO2020225551A1 (en) * 2019-05-08 2020-11-12 Oxford BioDynamics PLC Chromosome conformation markers of prostate cancer and lymphoma
CN110706749B (zh) * 2019-09-10 2022-06-10 至本医疗科技（上海）有限公司 一种基于组织器官分化层次关系的癌症类型预测系统和方法
GB201915464D0 (en) * 2019-10-24 2019-12-11 Uea Enterprises Ltd Novel biomarkers and diagnostic profiles for prostate cancer
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
KR102139313B1 (ko) * 2020-02-27 2020-07-29 이화여자대학교 산학협력단 알츠하이머병 치매 조기 진단을 위한 후성 유전학적 진단 키트 개발
KR102139315B1 (ko) * 2020-02-27 2020-07-29 이화여자대학교 산학협력단 Tnfrsf19 유전자의 dna 메틸레이션 변화를 이용한 알츠하이머병 치매 조기진단 마커
EP3960877A1 (en) * 2020-08-31 2022-03-02 Koninklijke Philips N.V. Prediction of a response of a prostate cancer subject to therapy or personalization of therapy of a prostate cancer subject
WO2022147503A1 (en) * 2020-12-31 2022-07-07 Tempus Labs, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
WO2023058100A1 (ja) 2021-10-04 2023-04-13 国立大学法人 東京大学 構造多型の検出方法、プライマーセット及びプライマーセットの設計方法
WO2024229244A2 (en) * 2023-05-03 2024-11-07 Mirvie, Inc. Methods and systems for determining a pregnancy-related state of a subject

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
WO1993017126A1 (en) 1992-02-19 1993-09-02 The Public Health Research Institute Of The City Of New York, Inc. Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids
US5583211A (en) 1992-10-29 1996-12-10 Beckman Instruments, Inc. Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US6090555A (en) 1997-12-11 2000-07-18 Affymetrix, Inc. Scanned image alignment systems and methods
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
DE69503126T2 (de) 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
EP0852004B1 (en) 1995-10-11 2011-01-19 Luminex Corporation Multiplexed analysis of clinical specimens
US5658734A (en) 1995-10-17 1997-08-19 International Business Machines Corporation Process for synthesizing chemical compounds
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
JP2000512744A (ja) 1996-05-16 2000-09-26 アフィメトリックス，インコーポレイテッド 標識材料を検出するシステムおよび方法
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
ATE234674T1 (de) 1996-11-14 2003-04-15 Affymetrix Inc Chemische amplifizierung zur synthese von musterordnungen
US6297006B1 (en) 1997-01-16 2001-10-02 Hyseq, Inc. Methods for sequencing repetitive sequences and for determining the order of sequence subfragments
US6023540A (en) 1997-03-14 2000-02-08 Trustees Of Tufts College Fiber optic sensor with encoded microspheres
US6327410B1 (en) 1997-03-14 2001-12-04 The Trustees Of Tufts College Target analyte sensors utilizing Microspheres
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6087102A (en) 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6428752B1 (en) 1998-05-14 2002-08-06 Affymetrix, Inc. Cleaning deposit devices that form microarrays and the like
US6287776B1 (en) 1998-02-02 2001-09-11 Signature Bioscience, Inc. Method for detecting and classifying nucleic acid hybridization
AU2586799A (en) 1998-02-06 1999-08-23 Affymetrix, Inc. Method of quality control in manufacturing processes
JP3944996B2 (ja) 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
US6031078A (en) 1998-06-16 2000-02-29 Millennium Pharmaceuticals, Inc. MTbx protein and nucleic acid molecules and uses therefor
US6277628B1 (en) 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
US6355431B1 (en) 1999-04-20 2002-03-12 Illumina, Inc. Detection of nucleic acid amplification reactions using bead arrays
US20030207295A1 (en) 1999-04-20 2003-11-06 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
HK1046156B (en) 1999-04-20 2009-01-23 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
US20040121364A1 (en) 2000-02-07 2004-06-24 Mark Chee Multiplex nucleic acid reactions
EP1259643B1 (en) 2000-02-07 2008-10-15 Illumina, Inc. Nucleic acid detection methods using universal priming
US6913884B2 (en) 2001-08-16 2005-07-05 Illumina, Inc. Compositions and methods for repetitive use of genomic DNA
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
US7955794B2 (en) 2000-09-21 2011-06-07 Illumina, Inc. Multiplex nucleic acid reactions
US6770441B2 (en) 2000-02-10 2004-08-03 Illumina, Inc. Array compositions and methods of making same
JP2001244419A (ja) * 2000-02-28 2001-09-07 Hitachi Ltd 高周波モジュール及び移動体検知モジュール
US6489606B1 (en) 2000-04-07 2002-12-03 Cidra Corporation Bragg grating sensor system with spectral response or code division multiplexing
JP2004513619A (ja) * 2000-07-07 2004-05-13 ヴィジゲン　バイオテクノロジーズ　インコーポレイテッド リアルタイム配列決定
US20040018491A1 (en) 2000-10-26 2004-01-29 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
US6964850B2 (en) * 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US8288641B2 (en) * 2001-12-27 2012-10-16 Intel Corporation Portable hand-held music synthesizer and networking method and apparatus
US20040029151A1 (en) * 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
AU2003265583C1 (en) 2002-08-20 2009-05-21 Cyvera Corporation Diffraction grating-based optical identification element
US20050227252A1 (en) 2002-08-20 2005-10-13 Moon John A Diffraction grating-based encoded articles for multiplexed experiments
US7164533B2 (en) 2003-01-22 2007-01-16 Cyvera Corporation Hybrid random bead/chip based microarray
US7441703B2 (en) 2002-08-20 2008-10-28 Illumina, Inc. Optical reader for diffraction grating-based encoded optical identification elements
WO2004024328A1 (en) 2002-09-12 2004-03-25 Cyvera Corporation Method and apparatus for aligning elongated microbeads in order to interrogate the same
WO2004025562A1 (en) 2002-09-12 2004-03-25 Cyvera Corp. Method and apparatus for labelling using diffraction grating-based encoded optical identification elements
US20040259105A1 (en) 2002-10-03 2004-12-23 Jian-Bing Fan Multiplex nucleic acid analysis using archived or fixed samples
AU2003300368A1 (en) * 2002-12-26 2004-07-29 Cemines, Llc. Methods and compositions for the diagnosis, prognosis, and treatment of cancer
US20050181394A1 (en) 2003-06-20 2005-08-18 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
EP1673614A1 (en) 2003-10-01 2006-06-28 CiDra Corporation Optical reader for diffraction grating-based encoded optical identification elements
US20060023310A1 (en) 2004-02-19 2006-02-02 Putnam Martin A Optical identification element using separate or partially overlapped diffraction gratings
US7339165B2 (en) 2004-07-09 2008-03-04 Hamilton Sundstrand Corporation Dual outlet pyrolyzer for biological agent detection system
DE602005019791D1 (de) 2004-11-16 2010-04-15 Illumina Inc Verfahren und vorrichtung zum lesen von kodierten mikrokugeln
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
WO2009046445A1 (en) 2007-10-04 2009-04-09 Halcyon Molecular Sequencing nucleic acid polymers with electron microscopy
US20120329713A1 (en) * 2008-02-21 2012-12-27 Klem Robert E Method for determining likelihood of clinical recurrence or clinically stable disease of prostate cancer after radical prostatectomy
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
TWM395976U (en) * 2010-06-30 2011-01-01 Tsung-Hung Wu Electret electroacoustic transducer
MX338883B (es) * 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
CA2827894A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CA2838736A1 (en) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer
SG11201404390WA (en) * 2012-01-31 2014-08-28 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
US20130323739A1 (en) * 2012-06-05 2013-12-05 Iris International, Inc. Method for determining recurrence or stable disease after treatment for prostate cancer
WO2014022594A1 (en) * 2012-07-31 2014-02-06 Daniel Mercola Stroma biomarkers for prostate cancer prognosis
CA2935720A1 (en) 2014-01-16 2015-07-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence

Also Published As

Publication number Publication date
AU2015206336A1 (en) 2016-07-14
US20200071770A1 (en) 2020-03-05
CA2935720A1 (en) 2015-07-23
HK1231515A1 (en) 2017-12-22
JP2017503527A (ja) 2017-02-02
US20220033915A1 (en) 2022-02-03
AU2022203428A1 (en) 2022-06-09
AU2020202145A1 (en) 2020-04-16
US10364469B2 (en) 2019-07-30
EP3094747B1 (en) 2018-11-07
CN105917008B (zh) 2020-11-27
US11098372B2 (en) 2021-08-24
WO2015109234A1 (en) 2015-07-23
US20160333420A1 (en) 2016-11-17
CN112322735A (zh) 2021-02-05
EP3094747A1 (en) 2016-11-23
AU2015206336B2 (en) 2020-01-23
CN105917008A (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
JP6666852B2 (ja) 前立腺がん再発の予後に関する遺伝子発現パネル
JP7042717B2 (ja) 癌の臨床転帰を予測する方法
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
US10196691B2 (en) Colon cancer gene expression signatures and methods of use
JP2017113008A (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
CA2623775A1 (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin
EP2125034A2 (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin
JP2011525106A (ja) 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
JP2015503923A (ja) 結腸直腸癌の解析のための方法およびバイオマーカー
JP2020191896A (ja) 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
US20160222461A1 (en) Methods and kits for diagnosing the prognosis of cancer patients
CA2989497A1 (en) Methods for diagnosis of bladder cancer
CN110806480B (zh) 肿瘤特异性细胞亚群和特征基因及其应用
HK40047245A (en) Gene expression panel for prognosis of prostate cancer recurrence
US11845993B2 (en) Methods for identifying prostate cancer
HK1231515B (en) Gene expression panel for prognosis of prostate cancer recurrence
WO2024118500A2 (en) Methods for detecting and treating ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200221

R150 Certificate of patent or registration of utility model

Ref document number: 6666852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees